ERBB2 oncogenic potential and cell surface availability have led to the development of targeted anti-ERBB2 antibodies, such as trastuzumab (Herceptin) that has become the standard care for patients with ERBB2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.